HRA’s Efficient Ella Development Strategy Begat FDA’s Efficient NDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The story of HRA Pharma’s emergency contraceptive Ella (ulipristal) bears many of the hallmarks of what many sponsors would consider a desirable regulatory path, culminating in a first-cycle approval with clean labeling.